6 result(s) displayed (1 - 6 of 6):

Bayer taps outsider as CEO, deals ahead? (from Corporate Dealmaker)

In about one year, Bayer AG's new CEO will be Thermo Fisher Scientific Inc.'s (NYSE:TMO) Marijn Dekkers. He has deal experience on a large scale, having led Thermo Electron Corp.'s $10.6 billion acquisition of Fisher Scientific International in 2006. Dekkers (pictured) will replace Werner Wenning, who held the post since...

Posted on September 15, 2009 10:23 AM

Post-Medarex acquisition targets (from Corporate Dealmaker)

Shares of late-stage oncology companies Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Seattle Genetics Inc. (NASDAQ:SGEN) are trading higher as the companies are seen as possible acquisition targets. They have similar specializations to Medarex Inc. (NASDAQ:MEDX), which is being acquired by Bristol-Myers Squibb Co. (NYSE:BMY) for $2.4 billion.A Reuters story on...

Posted on July 24, 2009 12:07 PM

Bristol's $2.4B Medarex buy advances trend (from Corporate Dealmaker)

Before releasing second-quarter earnings, cash-rich Bristol-Myers Squibb Co. (NYSE:BMY) said late Wednesday it's acquiring Medarex Inc. (NASDAQ: MEDX) for $2.4 billion, extending a string of recent deals in the oncology sector.Bristol chairman and CEO James Cornelius said in a statement, "Medarex's technology platform, people and pipeline provide a strong complement...

Posted on July 23, 2009 9:38 AM

Animal health M&A trend: Wockhardt sells (from Corporate Dealmaker)

In a broader effort to focus on its human pharmaceutical business and raise cash (as well as investor confidence), Indian generic drug maker Wockhardt Ltd. is selling its animal health division to France's Vétoquinol. The deal marks Vétoquinol's entrance into India. Earlier this month, Wockhardt sold its German business Esparma...

Posted on June 29, 2009 3:29 PM

Three more pharma megamergers to go? (from Corporate Dealmaker)

London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...

Posted on April 23, 2009 9:14 AM

Are method patents still valuable? (from Corporate Dealmaker)

Intellectual property issues are looming larger for most companies, but nowhere do they matter more than in the biotechnology industry. That is why a couple of recent decisions on so-called method patents in biotech have attracted such wide interest - and raised so many questions. The first case involved...

Posted on February 15, 2005 1:43 PM